NRx Pharmaceuticals (NASDAQ:NRXP) Upgraded by Wall Street Zen to Hold Rating

NRx Pharmaceuticals (NASDAQ:NRXP) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Sunday.

Other equities analysts have also recently issued reports about the company. D. Boral Capital restated a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. Ascendiant Capital Markets lifted their target price on NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Zacks Research upgraded NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. BTIG Research restated a “buy” rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, March 24th. Finally, HC Wainwright restated a “buy” rating and issued a $45.00 target price on shares of NRx Pharmaceuticals in a report on Monday, April 27th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.25.

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock opened at $3.84 on Friday. NRx Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $5.05. The stock has a market cap of $139.12 million, a PE ratio of -3.52 and a beta of 2.14. The business’s fifty day moving average is $3.19 and its 200-day moving average is $2.50.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $19.43 million. Equities research analysts predict that NRx Pharmaceuticals will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after buying an additional 37,598 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after purchasing an additional 82,781 shares during the period. Two Sigma Investments LP increased its stake in shares of NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the period. Anson Funds Management LP increased its stake in shares of NRx Pharmaceuticals by 26.2% in the third quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock worth $6,683,000 after purchasing an additional 420,129 shares during the period. Finally, One Wealth Management Investment & Advisory Services LLC increased its stake in shares of NRx Pharmaceuticals by 35.3% in the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock worth $103,000 after purchasing an additional 9,882 shares during the period. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.